News & Events – Page 9 – www.brainwork.md

23rd May 2018

“Ask the audience”: Stroke debates feature at ESOC 2018

https://www.brainwork.md/content/uploads/2018/05/Brainwork-StrokeContraversies.jpg 1600 2400 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 23rd May 2018 13th July 2018

Controversies in stroke were laid bare at the recent European Stroke Organisation Conference (ESOC) in Gothenburg, Sweden, in a special session that saw experts rallying…

Peter Stevenson, PhD
0
0

18th May 2018

First MS treatment approved for children & adolescents

https://www.brainwork.md/content/uploads/2018/05/Brainwork-MSAdolescents.jpg 1600 1067 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 18th May 2018 13th July 2018

The US Food and Drug Administration (FDA) has approved the use of fingolimod (Gilenya®, Novartis, Basel, Switzerland) for the treatment of paediatric patients aged 10…

Peter Stevenson, PhD
0
0

15th May 2018

Saunas linked to reduced stroke risk

https://www.brainwork.md/content/uploads/2018/05/Brainwork-StrokeRisk.jpg 1200 800 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 15th May 2018 13th July 2018

Regular use of saunas could be key in reducing stroke risk, a new European study reports. Baseline sauna habits of 1,628 men and women (age 53–74…

Peter Stevenson, PhD
0
0

9th May 2018

Start MS drugs early, say new guidelines

https://www.brainwork.md/content/uploads/2018/05/Brainwork-MSGuidelines.jpg 1400 885 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 9th May 2018 13th July 2018

Drug therapy for multiple sclerosis (MS) should be started early, according to updated guidelines from the American Academy of Neurology (AAN), which were presented at…

Peter Stevenson, PhD
0
1

30th April 2018

Solriamfetol improves wakefulness in narcolepsy patients

https://www.brainwork.md/content/uploads/2018/04/Brainwork-Solriamfetol.jpg 1920 1280 Lutz Achtnichts, MD Lutz Achtnichts, MD https://secure.gravatar.com/avatar/c84206ad1869ec28d770e94fa456ef6d?s=96&d=mm&r=g 30th April 2018 13th July 2018

This year’s American Academy of Neurology (AAN) meeting featured results of a randomised, placebo-controlled phase III study evaluating the safety and efficacy of solriamfetol for the treatment…

Lutz Achtnichts, MD
0
1

30th April 2018

Huntington’s disease: Antisense drug showing promising results

https://www.brainwork.md/content/uploads/2018/04/Brainwork-HuntingtonsDisease.jpg 4288 3216 Lutz Achtnichts, MD Lutz Achtnichts, MD https://secure.gravatar.com/avatar/c84206ad1869ec28d770e94fa456ef6d?s=96&d=mm&r=g 30th April 2018 13th July 2018

Results from a Phase I/IIa study of IONIS-HTTRx (RG6042) in Huntington’s disease (HD) were presented in a plenary session at the 2018 annual meeting of the American…

Lutz Achtnichts, MD
0
1

26th April 2018

Promising new migraine treatment presented at AAN 2018

https://www.brainwork.md/content/uploads/2018/04/Brainwork-Erenumab.jpg 5184 3456 Lutz Achtnichts, MD Lutz Achtnichts, MD https://secure.gravatar.com/avatar/c84206ad1869ec28d770e94fa456ef6d?s=96&d=mm&r=g 26th April 2018 13th July 2018

Migraine is consistently ranked among the top 20 most burdensome diseases worldwide. Until now, existing prophylactic therapies for episodic migraine consisted mostly of repurposed medications…

Lutz Achtnichts, MD
0
2

25th April 2018

A conversation with Dr Jens Kuhle

https://www.brainwork.md/content/themes/anemos/images/empty/thumbnail.jpg 150 150 Lutz Achtnichts, MD Lutz Achtnichts, MD https://secure.gravatar.com/avatar/c84206ad1869ec28d770e94fa456ef6d?s=96&d=mm&r=g 25th April 2018 13th July 2018

This week at AAN in Los Angeles, I had the opportunity to speak with Dr Jens Kuhle about a hot topic, neurofilaments in multiple sclerosis…

Lutz Achtnichts, MD
0
2

6th March 2018

ZINBRYTA^® (daclizumab) voluntarily withdrawn from markets worldwide

https://www.brainwork.md/content/uploads/2018/03/Brainwork-MS.jpg 1600 1067 Julien Ferrari, PharmD, PhD Julien Ferrari, PharmD, PhD https://secure.gravatar.com/avatar/3b67ea7b895dced9b9ed9795a9851ab4?s=96&d=mm&r=g 6th March 2018 13th July 2018

Biogen and AbbVie announced on 6 March 2018 a voluntary worldwide withdrawal of ZINBRYTA® (daclizumab) for relapsing MS, following reports of inflammatory encephalitis and meningoencephalitis among European patients. You…

Julien Ferrari, PharmD, PhD
0
2

7th February 2018

A new milestone in acute stroke treatment

https://www.brainwork.md/content/uploads/2018/02/Brainwork-Anewmilestone.jpg 6000 4000 Camilla Norrmén, PhD Camilla Norrmén, PhD https://secure.gravatar.com/avatar/c5fc8d4c102d9ee8db3f93d7f9c6ecd2?s=96&d=mm&r=g 7th February 2018 13th July 2018

Two recent studies have prompted the American Heart Association (AHA) to change their guidelines on early stroke management, extending the window of emergency stroke treatment up…

Camilla Norrmén, PhD
0
0

1st February 2018

From undercooked meat to neuralgic amyotrophy

https://www.brainwork.md/content/uploads/2018/02/MPR425-Brainwork-illustrations-HEV-HERO-image-V00-00-20180201-01.jpg 1920 1080 Michael Furrer, PhD Michael Furrer, PhD https://secure.gravatar.com/avatar/47c43996bf9448b78126dd0c38021678?s=96&d=mm&r=g 1st February 2018 13th July 2018

We have talked to Dr Paolo Ripellino from the Ospedale Civico di Lugano (EOC), Switzerland, about his research on neurological complications related to hepatitis E…

Michael Furrer, PhD
0
1

18th January 2018

80-year track record of neurosurgical success

https://www.brainwork.md/content/uploads/2018/01/Brainwork-80yearstrackrecord.jpg 1600 1605 Jared Ou-Young, MSc Jared Ou-Young, MSc https://secure.gravatar.com/avatar/1352535dba6be2a178b009ce2c0b64a3?s=96&d=mm&r=g 18th January 2018 13th July 2018

The UniversitätsSpital Zürich (USZ) reaches a milestone anniversary in 2017. From humble beginnings to now being one of the top-teaching institutions in Europe, USZ continues to lead…

Jared Ou-Young, MSc
0
1

“Ask the audience”: Stroke debates feature at ESOC 2018

First MS treatment approved for children & adolescents

​Saunas linked to reduced stroke risk

Start MS drugs early, say new guidelines​

Solriamfetol improves wakefulness in narcolepsy patients

​Huntington’s disease: Antisense drug showing promising results

​Promising new migraine treatment presented at AAN 2018

A conversation with Dr Jens Kuhle

ZINBRYTA® (daclizumab) voluntarily withdrawn from markets worldwide

​A new milestone in acute stroke treatment

From undercooked meat to neuralgic amyotrophy

​80-year track record of neurosurgical success

Saunas linked to reduced stroke risk

Start MS drugs early, say new guidelines

Huntington’s disease: Antisense drug showing promising results

Promising new migraine treatment presented at AAN 2018

ZINBRYTA^® (daclizumab) voluntarily withdrawn from markets worldwide

A new milestone in acute stroke treatment

80-year track record of neurosurgical success